159 related articles for article (PubMed ID: 31864917)
1. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study.
Walker JG; Kuchuloria T; Sergeenko D; Fraser H; Lim AG; Shadaker S; Hagan L; Gamkrelidze A; Kvaratskhelia V; Gvinjilia L; Aladashvili M; Asatiani A; Baliashvili D; Butsashvili M; Chikovani I; Khonelidze I; Kirtadze I; Kuniholm MH; Otiashvili D; Sharvadze L; Stvilia K; Tsertsvadze T; Zakalashvili M; Hickman M; Martin NK; Morgan J; Nasrullah M; Averhoff F; Vickerman P
Lancet Glob Health; 2020 Feb; 8(2):e244-e253. PubMed ID: 31864917
[TBL] [Abstract][Full Text] [Related]
2. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
3. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.
Lim AG; Qureshi H; Mahmood H; Hamid S; Davies CF; Trickey A; Glass N; Saeed Q; Fraser H; Walker JG; Mukandavire C; Hickman M; Martin NK; May MT; Averhoff F; Vickerman P
Int J Epidemiol; 2018 Apr; 47(2):550-560. PubMed ID: 29309592
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination.
Hagan LM; Kasradze A; Salyer SJ; Gamkrelidze A; Alkhazashvili M; Chanturia G; Chitadze N; Sukhiashvili R; Shakhnazarova M; Russell S; Blanton C; Kuchukhidze G; Baliashvili D; Hariri S; Ko S; Imnadze P; Drobeniuc J; Morgan J; Averhoff F
BMC Public Health; 2019 May; 19(Suppl 3):480. PubMed ID: 32326913
[TBL] [Abstract][Full Text] [Related]
5. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
[TBL] [Abstract][Full Text] [Related]
6. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
7. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
9. Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections.
Ayoub HH; Abu-Raddad LJ
BMJ Open; 2019 May; 9(5):e026600. PubMed ID: 31133586
[TBL] [Abstract][Full Text] [Related]
10. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
Ayoub HH; Abu-Raddad LJ
J Viral Hepat; 2017 Jun; 24(6):486-495. PubMed ID: 28039923
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
12. Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015.
Walker JG; Tskhomelidze I; Shadaker S; Tsereteli M; Handanagic S; Armstrong PA; Gamkrelidze A; Vickerman P
Euro Surveill; 2023 Jul; 28(30):. PubMed ID: 37498534
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.
Harris RJ; Harris HE; Mandal S; Ramsay M; Vickerman P; Hickman M; De Angelis D
J Viral Hepat; 2019 May; 26(5):541-551. PubMed ID: 30663179
[TBL] [Abstract][Full Text] [Related]
14. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
15. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
[TBL] [Abstract][Full Text] [Related]
16. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
[TBL] [Abstract][Full Text] [Related]
17. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
[TBL] [Abstract][Full Text] [Related]
19. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
[TBL] [Abstract][Full Text] [Related]
20. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
